Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1933 1
1947 3
1948 5
1949 1
1950 2
1951 2
1952 2
1955 1
1956 2
1957 10
1958 6
1959 4
1960 6
1961 4
1962 13
1963 12
1964 4
1965 6
1966 2
1967 4
1968 3
1969 1
1971 1
1972 2
1973 4
1974 6
1975 1
1976 6
1977 10
1978 10
1979 8
1980 11
1981 13
1982 27
1983 24
1984 26
1985 25
1986 22
1987 25
1988 39
1989 29
1990 39
1991 43
1992 42
1993 45
1994 72
1995 61
1996 76
1997 62
1998 45
1999 75
2000 74
2001 96
2002 118
2003 129
2004 150
2005 157
2006 177
2007 219
2008 223
2009 236
2010 260
2011 334
2012 362
2013 335
2014 385
2015 422
2016 414
2017 435
2018 443
2019 553
2020 649
2021 702
2022 725
2023 674
2024 624
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,751 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. Among authors: chu cy. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. André F, et al. Among authors: chu c. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Lancet. 2023. PMID: 37086745 Clinical Trial.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. Among authors: chu cy. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.
Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, Fan Y, Chan NT, Ma L, Liu J, Wang D, Dai X, Liu H, Ono M, Nakanishi A, Inuzuka H, North BJ, Huang YH, Sharma S, Geng Y, Xu W, Liu XS, Li L, Miki Y, Sicinski P, Freeman GJ, Wei W. Gao Y, et al. Among authors: chu c. Nat Cell Biol. 2020 Sep;22(9):1064-1075. doi: 10.1038/s41556-020-0562-4. Epub 2020 Aug 24. Nat Cell Biol. 2020. PMID: 32839551 Free PMC article.
Inulin fibre promotes microbiota-derived bile acids and type 2 inflammation.
Arifuzzaman M, Won TH, Li TT, Yano H, Digumarthi S, Heras AF, Zhang W, Parkhurst CN, Kashyap S, Jin WB, Putzel GG, Tsou AM, Chu C, Wei Q, Grier A; JRI IBD Live Cell Bank Consortium; Worgall S, Guo CJ, Schroeder FC, Artis D. Arifuzzaman M, et al. Among authors: chu c. Nature. 2022 Nov;611(7936):578-584. doi: 10.1038/s41586-022-05380-y. Epub 2022 Nov 2. Nature. 2022. PMID: 36323778 Free PMC article.
Gut-innervating nociceptors regulate the intestinal microbiota to promote tissue protection.
Zhang W, Lyu M, Bessman NJ, Xie Z, Arifuzzaman M, Yano H, Parkhurst CN, Chu C, Zhou L, Putzel GG, Li TT, Jin WB, Zhou J; JRI Live Cell Bank; Hu H, Tsou AM, Guo CJ, Artis D. Zhang W, et al. Among authors: chu c. Cell. 2022 Oct 27;185(22):4170-4189.e20. doi: 10.1016/j.cell.2022.09.008. Epub 2022 Oct 14. Cell. 2022. PMID: 36240781 Free PMC article.
ChIRP-MS: RNA-Directed Proteomic Discovery.
Chu C, Chang HY. Chu C, et al. Methods Mol Biol. 2018;1861:37-45. doi: 10.1007/978-1-4939-8766-5_3. Methods Mol Biol. 2018. PMID: 30218357
8,751 results